Diabetic Nephropathy – Current Treatment – Detailed, Expanded Analysis (US)
Diabetic nephropathy (DN), also known as diabetic kidney disease, refers to kidney function damage caused by diabetes. DN is a leading cause of chronic kidney disease (CKD) and is associated with high morbidity, mortality, and healthcare cost. Use of pharmacotherapy for DN varies by disease severity, physician specialty, and CKD stage. Physicians consider management of DN challenging because current therapies manage only the complications of DN. Currently available therapies have limited efficacy and are unable to treat the underlying cause of the disease and prevent progressive renal decline in patients. This report investigates the current prescribing practices for DN and analyzes the various factors driving treatment decisions.
QUESTIONS ANSWERED
- Do treatment decisions for DN differ based on disease progression and the specialty of the treating physician?
- Which attributes are most important in choosing drugs for the management of DN patients?
- How do physicians perceive standard-of-care therapies such as angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for DN?
- What is the level of satisfaction among physicians with currently available DN treatments? What is the level of familiarity and interest in products in the development pipeline?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use, so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
Table of contents
- Diabetic Nephropathy - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment | Diabetic Nephropathy | US | September 2019
Dwaipayan Chatterjee, M.Pharm., Senior Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders analyst. Mr. Chatterjee authors reports on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.